Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

Abstract

Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant and is indicated for the treatment of attention-deficit/hyperactivity disorder. A single-centre, double-blind, randomised, placebo-controlled, 6-period crossover study evaluated the abuse potential of single oral doses of 50, 100 (equivalent to 40 mg d-amphetamine), and 150 mg LDX, 40 mg d-amphetamine and 200 mg diethylpropion in 36 individuals with a history of stimulant abuse. On the primary abuse liability measure, maximum change of the Drug Rating Questionnaire-Subject Liking Scale compared with placebo, d-amphetamine and diethylpropion showed significant differences of 4.5 and 4.0 units, respectively (P < 0.001 for both vs placebo). LDX, administered at 50, 100 and 150 mg, showed nonsignificant differences of 2.0 and 2.1 units, respectively, at the two lower doses but a significant (P < 0.001 vs placebo) difference of 6.1 units at the highest dose. Subjects significantly favoured d-amphetamine 40 mg versus LDX 100 mg (2.4 units difference; P < 0.05). There was no significant difference in liking scores between d-amphetamine 40 mg and LDX 150 mg. Drug Rating Questionnaire-Subject Feel-Drug-Effect score was significantly lower for 100 mg LDX than for 40 mg d-amphetamine. There were no statistically significant differences between LDX and diethylpropion hydrochloride, a Schedule IV amphetamine-like stimulant, on abuse-related liking scores. Cardiovascular responses of LDX and d-amphetamine were similar at equivalent doses. In conclusion, at an equivalent amount of amphetamine base taken orally, LDX 100 mg had attenuated responses on measures of abuse liability compared with immediate-release d-amphetamine 40 mg. Abuse-related liking scores of LDX at a dose corresponding to a 50% higher amphetamine base (LDX 150 mg) were similar to d-amphetamine 40 mg.

Keywords

abuse ADHD LDX lisdexamfetamine stimulant Vyvanse

Get full access to this article

View all access options for this article.

References

American Academy of Child and Adolescent Psychiatry (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 47: 894–921.

American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement (2001) Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics 108: 1033–1044.

Biederman J Boellner SW Childress A Lopez FA Krishnan S Zhang Y (2007a) Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62: 970–976.

Biederman J Faraone SV (2005) Attention-deficit hyperactivity disorder. Lancet 366: 237–248.

Biederman J Krishnan S Zhang Y McGough JJ Findling RL (2007b) Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 29: 450–463.

Folstein MF Folstein SE McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189–198.

Jasinski D Krishnan S (2006) Pharmacokinetics of oral lisdexamfetamine dimesylate (LDX; NRP104) vs d-amphetamine in healthy adults with a history of stimulant abuse. Poster presented at: US Psychiatric and Mental Health 19th Annual Congress; November 15–19, 2006; New Orleans, LA.

Jasinski DR (2000) An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 14: 53–60.

Jasinski DR Kovacevic-Ristanovic R (2000) Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 23: 149–156.

10.

Jasinski DR Krishnan S (2006) Abuse liability of intravenous L-lysine-d-amphetamine (NRP104). Presented at: College on Problems of Drug Dependence 68th Annual Scientific Meeting; June 17–22, 2006; Scottsdale, AZ. Abstract 365.

11.

Jasinski DR Nutt JG Griffith JD (1974) Effects of diethylpropion and d-amphetamine after subcutaneous and oral administration. Clin Pharmacol Ther 16: 645–652.

12.

Krishnan S Jasinski D (2006) Pharmacokinetics of oral NRP104/SPD489 (lisdexamfetamine dimesylate) versus d-amphetamine in healthy adults with a history of stimulant abuse. Abstract presented at: The College on Problems of Drug Dependence 68th Annual Meeting; June 17–22, 2006; Scottsdale, AZ.

13.

Martin WR Sloan JW Sapira JD Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245–258.

14.

Pliszka SR Crismon ML Hughes CW Conners CK Emslie GJ Jensen PS ; Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder, et al. (2006) The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45: 642–657.

15.

Schuster CR (2006) History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 83(Suppl. 1): S8–S14.

16.

Shojaei A Ermer JC Krishnan S (2007) Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. Poster presented at: the 160th Annual Meeting of the American Psychiatric Association; May 19–24, 2007; San Diego, CA. Poster NR 740.

17.

Volkow ND Swanson JM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160: 1909–1918.

18.

Wigal SB Kollins SH Squires LA Childress AC Lisdexamfetamine dimesylate demonstrated efficacy throughout the day up to 13 hours in an analog classroom study in children with attention-deficit/hyperactivity disorder. Poster presented at: The American Academy of Child & Adolescent Psychiatry's 55th Annual Meeting; October 28-November 2, 2008; Chicago, IL.